section,entity_id,entity_name,entity_name_en,entity_type,category,attribute_path,value,evidence_source
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,name_en,Obesity,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,description,体内脂肪组织过度积累导致的慢性代谢性疾病,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,icd_10,E66,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,epidemiology.global_prevalence,成人肥胖率13.1%,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,epidemiology.china_prevalence,成人肥胖率7.0%，超重率34.3%,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,epidemiology.pediatric_prevalence,儿童肥胖率19.3%,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,epidemiology.economic_burden,全球医疗费用超过2万亿美元,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,epidemiology.mortality_risk,BMI每增加5kg/m²，死亡风险增加31%,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,classification.by_bmi.overweight.asian_criteria,BMI 23.0-27.4 kg/m²,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,classification.by_bmi.overweight.who_criteria,BMI 25.0-29.9 kg/m²,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,classification.by_bmi.obesity_class_1.asian_criteria,BMI 27.5-32.4 kg/m²,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,classification.by_bmi.obesity_class_1.who_criteria,BMI 30.0-34.9 kg/m²,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,classification.by_bmi.obesity_class_2.asian_criteria,BMI 32.5-37.4 kg/m²,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,classification.by_bmi.obesity_class_2.who_criteria,BMI 35.0-39.9 kg/m²,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,classification.by_bmi.obesity_class_3.asian_criteria,BMI ≥37.5 kg/m²,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,classification.by_bmi.obesity_class_3.who_criteria,BMI ≥40.0 kg/m²,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,classification.by_fat_distribution.android_obesity.pattern,腹型肥胖,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,classification.by_fat_distribution.android_obesity.measurement,腰围：男性≥90cm，女性≥85cm,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,classification.by_fat_distribution.android_obesity.risk,代谢风险高,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,classification.by_fat_distribution.gynoid_obesity.pattern,臀型肥胖,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,classification.by_fat_distribution.gynoid_obesity.measurement,臀围相对增大,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,classification.by_fat_distribution.gynoid_obesity.risk,代谢风险相对较低,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,classification.by_etiology.primary_obesity.percentage,95%,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,classification.by_etiology.primary_obesity.mechanism,能量摄入>消耗,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,classification.by_etiology.primary_obesity.factors,遗传; 环境; 行为,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,classification.by_etiology.secondary_obesity.percentage,5%,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,classification.by_etiology.secondary_obesity.endocrine_causes,库欣综合征; 甲状腺功能减退; 多囊卵巢综合征; 下丘脑性肥胖,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,classification.by_etiology.secondary_obesity.genetic_syndromes,Prader-Willi综合征; Bardet-Biedl综合征; 瘦素基因缺陷,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,classification.by_etiology.secondary_obesity.medications,糖皮质激素; 胰岛素; 抗精神病药物; 抗癫痫药物,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.energy_homeostasis.leptin_pathway.function,脂肪组织分泌瘦素抑制食欲,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.energy_homeostasis.leptin_pathway.obesity_effect,瘦素抵抗，饱腹感下降,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.energy_homeostasis.ghrelin_pathway.function,胃分泌胃饥饿素刺激食欲,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.energy_homeostasis.ghrelin_pathway.obesity_effect,餐后胃饥饿素下降不足,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.energy_homeostasis.hypothalamic_control.arcuate_nucleus,食欲调节中枢,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.energy_homeostasis.hypothalamic_control.neuropeptides,NPY; AgRP; POMC; CART,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.metabolic_dysfunction.insulin_resistance.mechanism,脂肪组织炎症→胰岛素抵抗,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.metabolic_dysfunction.insulin_resistance.consequences,糖耐量异常，2型糖尿病,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.metabolic_dysfunction.lipid_metabolism.free_fatty_acids,游离脂肪酸增加,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.metabolic_dysfunction.lipid_metabolism.dyslipidemia,TG升高，HDL-C降低,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.metabolic_dysfunction.inflammation.adipokines,脂肪因子失衡,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.metabolic_dysfunction.inflammation.cytokines,TNF-α、IL-6升高,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.metabolic_dysfunction.inflammation.crp,C反应蛋白升高,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.physical_findings.anthropometry,体重指数增加; 腰围增大; 体脂率升高,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.physical_findings.body_habitus,向心性肥胖; 颈部脂肪垫; 皮肤皱褶增多,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.metabolic_complications.diabetes,2型糖尿病风险增加2-6倍,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.metabolic_complications.dyslipidemia,血脂异常患病率60-70%,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.metabolic_complications.hypertension,高血压患病率是正常体重者2-3倍,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.metabolic_complications.metabolic_syndrome,代谢综合征患病率40-50%,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.cardiovascular_complications.coronary_heart_disease,冠心病风险增加2-3倍,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.cardiovascular_complications.stroke,脑卒中风险增加1.5-2倍,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.cardiovascular_complications.heart_failure,心力衰竭风险增加2倍,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.cardiovascular_complications.arrhythmia,房颤风险增加,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.other_complications.sleep_apnea,睡眠呼吸暂停综合征,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.other_complications.fatty_liver,非酒精性脂肪肝,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.other_complications.gallstones,胆石症,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.other_complications.osteoarthritis,骨关节炎,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.other_complications.cancer_risk,结直肠癌、乳腺癌风险增加,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.other_complications.reproductive_disorders,生殖功能障碍,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,diagnostic_assessment.anthropometric_measurements.bmi,体重指数 = 体重(kg)/身高²(m²),ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,diagnostic_assessment.anthropometric_measurements.waist_circumference,腰围测量,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,diagnostic_assessment.anthropometric_measurements.waist_hip_ratio,腰臀比,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,diagnostic_assessment.anthropometric_measurements.body_fat_percentage,体脂率测定,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,diagnostic_assessment.body_composition.dexa_scan,双能X线吸收测定,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,diagnostic_assessment.body_composition.bioelectrical_impedance,生物电阻抗分析,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,diagnostic_assessment.body_composition.underwater_weighing,水下称重法,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,diagnostic_assessment.body_composition.air_displacement,空气置换法,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,diagnostic_assessment.metabolic_evaluation.glucose_metabolism,空腹血糖; 餐后2小时血糖; 糖化血红蛋白; OGTT,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,diagnostic_assessment.metabolic_evaluation.lipid_profile,总胆固醇; 甘油三酯; LDL-C; HDL-C,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,diagnostic_assessment.metabolic_evaluation.hormonal_assessment,甲状腺功能; 皮质醇节律; 性激素水平; 瘦素水平,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,diagnostic_assessment.complication_screening.cardiovascular,心电图、超声心动图,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,diagnostic_assessment.complication_screening.hepatic,肝功能、肝脏超声,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,diagnostic_assessment.complication_screening.sleep_disorders,多导睡眠监测,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,diagnostic_assessment.complication_screening.psychological,抑郁、焦虑评估,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.dietary_modification.caloric_restriction,热量限制500-750kcal/日,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.dietary_modification.macronutrient_distribution.carbohydrate,45-65%总热量,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.dietary_modification.macronutrient_distribution.protein,10-35%总热量,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.dietary_modification.macronutrient_distribution.fat,20-35%总热量,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.dietary_modification.dietary_patterns,地中海饮食; DASH饮食; 低血糖指数饮食; 间歇性禁食,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.dietary_modification.portion_control,控制食物分量,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.dietary_modification.meal_timing,规律进餐时间,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.physical_activity.aerobic_exercise.frequency,每周≥150分钟中等强度,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.physical_activity.aerobic_exercise.intensity,50-70%最大心率,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.physical_activity.aerobic_exercise.types,快走; 游泳; 骑车; 慢跑,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.physical_activity.resistance_training.frequency,每周≥2次,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.physical_activity.resistance_training.benefits,增加肌肉量，提高代谢率,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.physical_activity.daily_activity,增加日常身体活动,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.behavioral_modification.goal_setting,设定现实可达成目标,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.behavioral_modification.self_monitoring,体重、饮食、运动记录,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.behavioral_modification.cognitive_therapy,认知行为治疗,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.behavioral_modification.social_support,家庭和社会支持系统,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.fda_approved_medications.orlistat.mechanism,胰脂肪酶抑制剂,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.fda_approved_medications.orlistat.dose,120mg tid 餐时服用,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.fda_approved_medications.orlistat.efficacy,减重5-10%,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.fda_approved_medications.orlistat.side_effects,胃肠道不适、脂溶性维生素缺乏,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.fda_approved_medications.liraglutide.mechanism,GLP-1受体激动剂,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.fda_approved_medications.liraglutide.dose,3.0mg/日 皮下注射,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.fda_approved_medications.liraglutide.efficacy,减重8-12%,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.fda_approved_medications.liraglutide.side_effects,恶心、腹泻、胰腺炎风险,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.fda_approved_medications.semaglutide.mechanism,GLP-1受体激动剂,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.fda_approved_medications.semaglutide.dose,2.4mg/周 皮下注射,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.fda_approved_medications.semaglutide.efficacy,减重15-20%,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.fda_approved_medications.semaglutide.side_effects,胃肠道反应,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.fda_approved_medications.naltrexone_bupropion.mechanism,阿片受体拮抗剂+去甲肾上腺素再摄取抑制剂,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.fda_approved_medications.naltrexone_bupropion.dose,16mg/180mg bid,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.fda_approved_medications.naltrexone_bupropion.efficacy,减重5-9%,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.fda_approved_medications.naltrexone_bupropion.contraindications,癫痫、厌食症,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.selection_criteria.bmi_threshold,BMI≥30 kg/m² 或 BMI≥27 kg/m²+合并症,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.selection_criteria.lifestyle_failure,生活方式干预6个月效果不佳,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.selection_criteria.contraindications,妊娠、严重精神疾病,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.bariatric_surgery.indications.class_3_obesity,BMI≥40 kg/m²,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.bariatric_surgery.indications.class_2_with_comorbidities,BMI≥35 kg/m²+严重合并症,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.bariatric_surgery.indications.asian_criteria,BMI≥37.5 kg/m² 或 BMI≥32.5 kg/m²+合并症,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.bariatric_surgery.procedures.sleeve_gastrectomy.mechanism,胃容量减少75-80%,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.bariatric_surgery.procedures.sleeve_gastrectomy.weight_loss,50-70%超重体重,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.bariatric_surgery.procedures.sleeve_gastrectomy.complications,胃漏、狭窄,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.bariatric_surgery.procedures.roux_en_y_gastric_bypass.mechanism,限制性+吸收不良,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.bariatric_surgery.procedures.roux_en_y_gastric_bypass.weight_loss,60-80%超重体重,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.bariatric_surgery.procedures.roux_en_y_gastric_bypass.complications,吻合口漏、营养缺乏,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.bariatric_surgery.procedures.adjustable_gastric_banding.mechanism,可调节胃束带,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.bariatric_surgery.procedures.adjustable_gastric_banding.weight_loss,40-50%超重体重,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.bariatric_surgery.procedures.adjustable_gastric_banding.complications,带子滑脱、糜烂,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.bariatric_surgery.outcomes.weight_loss,术后2年维持减重50-70%,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.bariatric_surgery.outcomes.diabetes_remission,2型糖尿病缓解率60-80%,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.bariatric_surgery.outcomes.cardiovascular_benefits,心血管风险显著降低,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.bariatric_surgery.outcomes.mortality_reduction,全因死亡率降低30-40%,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,monitoring.weight_management,每周称重; 腰围测量; 体脂率监测,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,monitoring.metabolic_parameters,血糖、糖化血红蛋白; 血脂谱; 血压; 肝功能,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,monitoring.nutritional_status,蛋白质营养状态; 维生素B12、叶酸; 脂溶性维生素; 微量元素,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,monitoring.complication_surveillance,心血管风险评估; 糖尿病筛查; 睡眠呼吸暂停评估; 心理健康评估,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,prognosis.weight_loss_maintenance,5年维持减重成功率20-30%,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,prognosis.health_benefits,减重5-10%即可显著改善代谢指标,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,prognosis.mortality_impact,BMI降低可显著降低死亡风险,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,prognosis.quality_of_life,减重改善生活质量和心理健康,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,name_en,Metabolic Syndrome,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,description,以胰岛素抵抗为核心的代谢异常综合征,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,icd_10,E88.81,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,epidemiology.global_prevalence,成人患病率20-25%,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,epidemiology.china_prevalence,成人患病率13.8%,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,epidemiology.age_trend,患病率随年龄增长而增加,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,epidemiology.gender_difference,绝经后女性患病率高于男性,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,diagnostic_criteria.idf_2005.central_obesity,必需条件：腰围男性≥90cm，女性≥80cm,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,diagnostic_criteria.idf_2005.plus_two_of,TG≥1.7mmol/L或已治疗; HDL-C：男性<1.03mmol/L，女性<1.29mmol/L; BP≥130/85mmHg或已治疗; FPG≥5.6mmol/L或已诊断糖尿病,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,diagnostic_criteria.ncep_atp_iii.criteria,以下5项中≥3项,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,diagnostic_criteria.ncep_atp_iii.components,腰围：男性>102cm，女性>88cm; TG≥1.7mmol/L; HDL-C：男性<1.03mmol/L，女性<1.29mmol/L; BP≥130/85mmHg; FPG≥5.6mmol/L,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,diagnostic_criteria.who_1999.glucose_intolerance,必需条件：糖耐量受损或糖尿病,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,diagnostic_criteria.who_1999.plus_two_of,腰臀比：男性>0.90，女性>0.85; TG≥1.7mmol/L或HDL-C<0.9mmol/L; BP≥140/90mmHg; 尿白蛋白排泄率≥20μg/min,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.insulin_resistance.central_mechanism,胰岛素抵抗是核心机制,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.insulin_resistance.tissue_effects.muscle,骨骼肌糖摄取减少,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.insulin_resistance.tissue_effects.liver,肝糖输出增加，脂肪合成增加,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.insulin_resistance.tissue_effects.adipose,脂肪分解增加，瘦素抵抗,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.insulin_resistance.compensatory_hyperinsulinemia,代偿性高胰岛素血症,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.inflammatory_pathway.adipose_inflammation,脂肪组织慢性炎症,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.inflammatory_pathway.cytokines,TNF-α、IL-6、CRP升高,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.inflammatory_pathway.adipokines,脂联素下降，瘦素抵抗,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.oxidative_stress.ros_production,活性氧产生增加,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.oxidative_stress.antioxidant_depletion,抗氧化能力下降,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.oxidative_stress.endothelial_dysfunction,血管内皮功能受损,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.metabolic_features.glucose_metabolism,空腹血糖受损; 糖耐量异常; 2型糖尿病; 胰岛素抵抗,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.metabolic_features.lipid_abnormalities,高甘油三酯血症; 低HDL胆固醇血症; 小而密LDL颗粒增多; 载脂蛋白B升高,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.metabolic_features.blood_pressure,收缩压升高; 舒张压升高; 脉压差增大,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.body_composition.central_obesity,向心性肥胖,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.body_composition.visceral_adiposity,内脏脂肪增加,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.body_composition.subcutaneous_fat,皮下脂肪分布异常,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.body_composition.muscle_mass,肌肉质量相对减少,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.vascular_complications.endothelial_dysfunction,血管内皮功能障碍,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.vascular_complications.arterial_stiffness,动脉硬化,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.vascular_complications.microalbuminuria,微量白蛋白尿,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.vascular_complications.carotid_thickness,颈动脉内膜中层厚度增加,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,complications.cardiovascular_disease.risk_increase,心血管疾病风险增加2-3倍,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,complications.cardiovascular_disease.manifestations,冠心病; 脑卒中; 外周血管病; 心房颤动,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,complications.diabetes_risk.progression,进展为2型糖尿病风险增加5倍,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,complications.diabetes_risk.timeline,10年糖尿病发病率30-50%,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,complications.other_complications,非酒精性脂肪肝; 多囊卵巢综合征; 睡眠呼吸暂停; 慢性肾脏病; 某些恶性肿瘤,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.weight_management.target,减重5-10%,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.weight_management.caloric_restriction,热量限制500-1000kcal/日,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.weight_management.dietary_composition,低糖、适量蛋白、健康脂肪,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.physical_activity.aerobic_exercise,每周≥150分钟中等强度,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.physical_activity.resistance_training,每周≥2次力量训练,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.physical_activity.daily_activity,增加日常活动量,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.dietary_patterns.mediterranean_diet,地中海饮食模式,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.dietary_patterns.dash_diet,DASH饮食,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.dietary_patterns.low_glycemic_index,低血糖指数饮食,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_intervention.dietary_patterns.portion_control,控制食物分量,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.glucose_management.metformin,首选药物，改善胰岛素敏感性,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.glucose_management.glp1_agonists,GLP-1受体激动剂,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.glucose_management.sglt2_inhibitors,SGLT-2抑制剂,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.glucose_management.pioglitazone,噻唑烷二酮类,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.lipid_management.statins,他汀类药物,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.lipid_management.fibrates,贝特类药物(高TG),ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.lipid_management.ezetimibe,依折麦布,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.lipid_management.pcsk9_inhibitors,PCSK9抑制剂,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.blood_pressure_control.ace_inhibitors,ACE抑制剂,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.blood_pressure_control.arbs,血管紧张素受体阻滞剂,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.blood_pressure_control.calcium_blockers,钙通道阻滞剂,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.blood_pressure_control.diuretics,利尿剂,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.target_goals.glucose_control.hba1c,<7.0% (糖尿病患者),ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.target_goals.glucose_control.fpg,4.4-7.0mmol/L,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.target_goals.glucose_control.ppg,<10.0mmol/L,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.target_goals.lipid_targets.ldl_c,<2.6mmol/L (高危患者<1.8mmol/L),ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.target_goals.lipid_targets.hdl_c,男性>1.0mmol/L，女性>1.3mmol/L,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.target_goals.lipid_targets.tg,<1.7mmol/L,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.target_goals.blood_pressure,<130/80mmHg,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.target_goals.weight,减重5-10%或BMI<25kg/m²,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,monitoring.metabolic_parameters,血糖、糖化血红蛋白每3-6个月; 血脂谱每3-6个月; 血压每次就诊; 体重、腰围每次就诊,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,monitoring.cardiovascular_risk,心电图每年; 超声心动图(如有指征); 颈动脉超声; 踝臂指数,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,monitoring.complication_screening,眼底检查; 肾功能、尿蛋白; 肝功能; 甲状腺功能,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,prognosis.cardiovascular_outcomes,积极治疗可显著降低心血管风险,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,prognosis.diabetes_prevention,生活方式干预可延缓或预防糖尿病,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,prognosis.reversibility,早期干预代谢综合征可逆转,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,prognosis.long_term_management,需要长期综合管理,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,name_en,Insulin Resistance Syndrome,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,description,胰岛素生物学效应降低引起的代谢紊乱综合征,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,icd_10,E88.81,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,epidemiology.prevalence,成人患病率25-30%,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,epidemiology.risk_factors,遗传易感性; 腹型肥胖; 久坐生活方式; 高糖高脂饮食; 年龄增长; 多囊卵巢综合征,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.molecular_mechanisms.insulin_signaling.receptor_defects,胰岛素受体敏感性下降,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.molecular_mechanisms.insulin_signaling.post_receptor,受体后信号转导异常,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.molecular_mechanisms.insulin_signaling.glucose_transporters,GLUT4转位受损,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.molecular_mechanisms.free_fatty_acids.randle_cycle,糖脂代谢竞争性抑制,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.molecular_mechanisms.free_fatty_acids.lipotoxicity,游离脂肪酸脂毒性,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.molecular_mechanisms.free_fatty_acids.inflammatory_cytokines,炎症因子激活,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.molecular_mechanisms.mitochondrial_dysfunction.oxidative_capacity,氧化代谢能力下降,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.molecular_mechanisms.mitochondrial_dysfunction.atp_synthesis,ATP合成效率降低,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.molecular_mechanisms.mitochondrial_dysfunction.ros_production,活性氧产生增加,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,clinical_assessment.laboratory_tests.homa_ir.calculation,HOMA-IR = FPG×FINS/22.5,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,clinical_assessment.laboratory_tests.homa_ir.normal_range,<2.5,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,clinical_assessment.laboratory_tests.homa_ir.interpretation,≥2.5提示胰岛素抵抗,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,clinical_assessment.laboratory_tests.insulin_tolerance_test.method,胰岛素耐量试验,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,clinical_assessment.laboratory_tests.insulin_tolerance_test.normal_response,血糖下降>50%,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,clinical_assessment.laboratory_tests.insulin_tolerance_test.abnormal,血糖下降<30%,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,clinical_assessment.laboratory_tests.hyperinsulinemic_clamp.gold_standard,高胰岛素正血糖钳夹试验,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,clinical_assessment.laboratory_tests.hyperinsulinemic_clamp.glucose_disposal,葡萄糖处置率,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,clinical_assessment.laboratory_tests.hyperinsulinemic_clamp.clinical_utility,主要用于研究,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,clinical_assessment.biomarkers.adiponectin,脂联素水平降低,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,clinical_assessment.biomarkers.leptin,瘦素水平升高,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,clinical_assessment.biomarkers.c_peptide,C肽水平评估β细胞功能,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,clinical_assessment.biomarkers.proinsulin,胰岛素原/胰岛素比值升高,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.insulin_sensitizers.metformin.mechanism,减少肝糖输出，增加肌肉糖摄取,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.insulin_sensitizers.metformin.dose,500-2000mg/日,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.insulin_sensitizers.metformin.benefits,改善胰岛素敏感性，减重,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.insulin_sensitizers.pioglitazone.mechanism,PPARγ激动剂,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.insulin_sensitizers.pioglitazone.dose,15-45mg/日,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.insulin_sensitizers.pioglitazone.benefits,显著改善胰岛素敏感性,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.insulin_sensitizers.pioglitazone.side_effects,体重增加，水肿，骨折风险,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.insulin_sensitizers.rosiglitazone.mechanism,PPARγ激动剂,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.insulin_sensitizers.rosiglitazone.concerns,心血管安全性争议,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.insulin_sensitizers.rosiglitazone.status,使用受限,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_modifications.exercise_training.aerobic_exercise,提高胰岛素敏感性30-50%,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_modifications.exercise_training.resistance_training,增加肌肉质量和糖摄取,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_modifications.exercise_training.timing,运动后胰岛素敏感性改善持续48小时,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_modifications.dietary_interventions.caloric_restriction,体重减轻改善胰岛素敏感性,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_modifications.dietary_interventions.macronutrient_composition,低升糖指数饮食,ADA Standards of Medical Care in Diabetes 2025
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.lifestyle_modifications.dietary_interventions.meal_timing,间歇性禁食可能有益,ADA Standards of Medical Care in Diabetes 2025
